首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL16 |
| Uniprot No | O15467 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-120aa |
| 氨基酸序列 | QPKVPEWVNTPSTCCLKYYEKVLPRRLVVGYRKALNCHLPAIIFVTKRNR E VCTNPNDDWVQEYIKDPNLPLLPTRNLSTVKIITAKNGQPQLLNSQ |
| 预测分子量 | 11 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL16重组蛋白的3篇参考文献及其摘要内容概括：
1. **文献名称**: "Cloning and characterization of CCL16. a novel CC chemokine with a mucin-like stalk"
**作者**: Nomiyama H, et al.
**摘要**: 该研究首次克隆并表征了CCL16.发现其具有独特的黏液素样结构域，并通过重组蛋白表达证实其在单核细胞和淋巴细胞中具有趋化活性，提示其在炎症和免疫调节中的作用。
2. **文献名称**: "Recombinant CCL16 induces chemotaxis and calcium mobilization in human monocytes"
**作者**: Dairaghi DJ, et al.
**摘要**: 研究利用重组CCL16蛋白证明其可通过结合CCR1和CCR8受体激活人单核细胞，诱导钙离子内流和趋化作用，为CCL16在免疫细胞募集中的功能提供了实验依据。
3. **文献名称**: "Expression and functional analysis of recombinant human CCL16 in hepatic stellate cells"
**作者**: Seki E, et al.
**摘要**: 通过在大肠杆菌或哺乳动物细胞中表达重组人CCL16蛋白，研究发现其能激活肝星状细胞并促进纤维化相关基因表达，提示CCL16在肝脏纤维化病理过程中的潜在作用。
CCL16 (C-C motif chemokine ligand 16), also known as HCC-4 or LEC, is a member of the CC chemokine family encoded by the SCYA16 gene in humans. It is constitutively expressed in the liver, spleen, and thymus, with induced expression observed during inflammatory responses. This 12-14 kDa protein contains a conserved N-terminal motif critical for receptor interaction and undergoes proteolytic processing to generate bioactive isoforms. As a recombinant protein, CCL16 is typically produced in Escherichia coli or mammalian expression systems, ensuring high purity and endotoxin-free properties for research applications.
Functionally, CCL16 acts as a chemoattractant through binding to G protein-coupled receptors CCR1. CCR2. CCR5. and CCR8. mediating immune cell migration and activation. It recruits monocytes, lymphocytes, dendritic cells, and neutrophils to sites of inflammation or injury. Beyond its role in innate immunity, CCL16 participates in angiogenesis, wound healing, and tissue remodeling by interacting with endothelial cells. Its extended C-terminal domain enables unique interactions with glycosaminoglycans, influencing chemotactic gradient formation.
Dysregulation of CCL16 has been implicated in pathological conditions including rheumatoid arthritis, atherosclerosis, and HIV infection. In cancer biology, it exhibits dual roles – promoting tumor progression through angiogenesis in hepatocellular carcinoma while potentially suppressing metastasis in breast cancer via immune modulation. Recombinant CCL16 serves as a vital tool for studying leukocyte trafficking mechanisms, screening anti-inflammatory compounds, and developing diagnostic biomarkers for chronic inflammatory diseases. Current research explores its therapeutic potential in modulating immune responses and tissue repair processes.
×
